Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients

• Christian Burkhardt ,

  * E-mail: christian.burkhardt@kssg.ch

  Affiliation ALS Clinic/Neuromuscular Diseases Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland

  http://orcid.org/0000-0002-8606-7905

  ⨯
• Christoph Neuwirth,

  Affiliation ALS Clinic/Neuromuscular Diseases Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland

  ⨯
• Andreas Sommacal,

  Affiliation Department of Pathology, Kantonsspital St. Gallen, St. Gallen, Switzerland

  ⨯
• Peter M. Andersen,

  Affiliation Institute of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden

  ⨯
• Markus Weber

  Affiliation ALS Clinic/Neuromuscular Diseases Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland

  ⨯